Reporting owner · CIK 0001992324

Savitz Ryan

SEC Form 4 history for the last 180 days across 1 company, 29 transactions and 1 filing.

EVP, CFO, CBOEVP, CFO & CBODianthus Therapeutics, Inc. DE
Open-market transaction mix0% buys0 buys · 9 sales

Period: Last 180 days

Trade dates in this period: Nov 9, 2026 – Nov 12, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$00 purchases
Selling$11.2M9 sales
Net value−$11.2MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Savitz Ryan transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$1.61MView disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$362kView disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$29.2kView disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$274kView disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$28.7kView disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$38.0kView disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$231kView disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$27.8kView disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$28.3kView disclosure →
DNTHDianthus Therapeutics, Inc. DE
Executive Vice President · Chief Financial Officer · CBO
EVP, CFO, CBO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$189kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at Dianthus Therapeutics, Inc. DE on Nov 12, 2026 valued at $1,605,085.44.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Nov 202609$0$11,228,719.74−$11,228,719.74

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$1.25M
Median P/S size$231k
Direct29
Indirect0
Nov 12, 2026exercise

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

19 observations · Nov 9, 2026 – Nov 12, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 12, 20260 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Nov 9, 202629,276Nov 12, 2026View transaction
Nov 9, 202649,884Nov 12, 2026View transaction
Nov 9, 202690,314Nov 12, 2026View transaction
Nov 9, 2026100,713Nov 12, 2026View transaction
Nov 9, 2026100,413Nov 12, 2026View transaction
Nov 9, 202699,713Nov 12, 2026View transaction
Nov 9, 202697,977Nov 12, 2026View transaction
Nov 9, 202660,460Nov 12, 2026View transaction
Nov 9, 20262,064Nov 12, 2026View transaction
Nov 9, 20260Nov 12, 2026View transaction
Nov 10, 20261,301Nov 12, 2026View transaction
Nov 10, 20262,561Nov 12, 2026View transaction
Nov 10, 20260Nov 12, 2026View transaction
Nov 11, 20261,744Nov 12, 2026View transaction
Nov 11, 20263,044Nov 12, 2026View transaction
Nov 11, 20260Nov 12, 2026View transaction
Nov 12, 20261,339Nov 12, 2026View transaction
Nov 12, 202617,724Nov 12, 2026View transaction
Nov 12, 20260Nov 12, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Savitz Ryan Insider Activity FAQ

SEC Form 4 context

Who is Savitz Ryan?

Savitz Ryan is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001992324.

Which companies has Savitz Ryan reported transactions for?

Dianthus Therapeutics, Inc. DE

When was Savitz Ryan's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Savitz Ryan's latest insider sale?

The insider reported a sale at Dianthus Therapeutics, Inc. DE on Nov 12, 2026 valued at $1,605,085.44.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.